---
layout: default
title: Toremifene
parent: 僅模型預測 (L5)
nav_order: 407
evidence_level: L5
indication_count: 1
---

# Toremifene
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Toremifene: From Unrecorded Original Indication to HIV Infectious Disease

## One-Sentence Summary

Toremifene is a selective estrogen receptor modulator (SERM), historically related to tamoxifen and used in breast cancer treatment; its original approved indication is not documented in the current evidence pack, and the drug is **not marketed in Germany**. The TxGNN model predicts it may be effective for **HIV infectious disease**, but this is currently supported by only **1 in vitro mechanistic publication** and **no clinical trials** — the evidence base is very preliminary.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in evidence pack |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L5 |
| Germany Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on the available literature, toremifene is a selective estrogen receptor modulator (SERM) pharmacologically related to the breast cancer drug tamoxifen.

The only supporting publication (PMID 24520056) is an *in vitro* mechanistic study showing that estrogen receptor antagonists (including tamoxifen and toremifene) can directly bind fungal EF-hand (calcium-binding) proteins, giving them anti-cryptococcal activity against *Cryptococcus neoformans* — a common opportunistic infection in HIV/AIDS patients — rather than a direct antiretroviral effect on HIV itself.

This means the mechanistic link between toremifene and the predicted indication "HIV infectious disease" is **indirect**: the drug title and study content concern antifungal activity against an HIV-associated opportunistic pathogen, not the HIV virus directly. The high TxGNN score (99.41%) likely reflects knowledge-graph proximity between HIV and cryptococcosis (a known comorbidity) rather than a direct antiviral mechanism. No clinical trial evidence exists to support this prediction.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [24520056](https://pubmed.ncbi.nlm.nih.gov/24520056/) | 2014 | In vitro mechanistic study | mBio | Estrogen receptor antagonists (tamoxifen, toremifene) show fungicidal activity against *Cryptococcus neoformans* by binding fungal EF-hand proteins; synergizes with fluconazole and amphotericin B in vitro — relevant to HIV-associated cryptococcosis, not HIV itself |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Evidence level is L5 — the only support is a single *in vitro* mechanistic study with an indirect link (antifungal activity against an HIV-associated opportunistic infection, not a direct antiviral mechanism), and there are zero clinical trials. This does not meet the threshold to advance to safety screening (S1).

**To proceed, the following is needed:**
- TFDA/BfArM package insert with warnings and contraindications (currently blocking — DG001)
- Confirmed mechanism of action (DrugBank query — DG002)
- Direct evidence of anti-HIV or anti-cryptococcal activity in vivo/clinically, not just in vitro
- Clarification of toremifene's original approved indication for comparative mechanistic analysis
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

